Journal article
Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
Gloria Iacoboni, Emil Ramsø Kyvsgaard, Victor Navarro Garces, David A Russler-Germain, Alejandro Martín García-Sancho, Philip A Thompson, Dylan Therwhanger, Itziar Carro, David Quintela, Pilar Gómez, Evelyn Valencia, Gala Vega, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Angel Serna, Simon Husby, Beatriz De La Cruz, Jing Luan, Sergi Camarillas, Lucia Medina Show all
Blood | American Society of Hematology | Published : 2024
Abstract
Introduction: Bispecific antibodies (BsAbs) are approved for patients with relapsed/refractory (R/R) follicular lymphoma (FL) based on single-arm clinical trials. These T-cell engaging agents achieve approximately 60% complete response rate (CRR), but information regarding real-world prognostic factors is scarce. In light of the deleterious impact of pre-treatment bendamustine (benda) exposure on chimeric antigen receptor (CAR) T-cell outcomes, and given the similar mechanism of action, we aimed to assess the impact that this alkylating agent has on BsAbs outcomes in R/R FL patients. Methods: We conducted a multicenter, international stud..
View full abstract